Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
Pöttgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, Heinzelmann F, Cordes S, Schuler MH, Welter S, Stamatis G, Friedel G, Darwiche K, Jöckel KH, Eberhardt W, Stuschke M. Pöttgen C, et al. Among authors: stamatis g. J Clin Oncol. 2016 Jul 20;34(21):2526-33. doi: 10.1200/JCO.2015.65.5167. Epub 2016 May 31. J Clin Oncol. 2016. PMID: 27247220 Clinical Trial.
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.
Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, Gauler T, Antoch G, Bockisch A, Stuschke M. Pöttgen C, et al. Among authors: stamatis g. Clin Cancer Res. 2006 Jan 1;12(1):97-106. doi: 10.1158/1078-0432.CCR-05-0510. Clin Cancer Res. 2006. PMID: 16397030 Free article.
Multimodality treatment of stage IIIA and IIIB non-small cell lung cancer.
Eberhardt W, Gauler T, Pöttgen C, Krbek T, Korfee S, Stamatis G, Stuschke M. Eberhardt W, et al. Among authors: stamatis g. J Thorac Oncol. 2007 May;2(5 Suppl):S35-6. doi: 10.1097/01.JTO.0000268640.56073.d1. J Thorac Oncol. 2007. PMID: 17457229 Free article. No abstract available.
Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial.
Pöttgen C, Eberhardt W, Grannass A, Korfee S, Stüben G, Teschler H, Stamatis G, Wagner H, Passlick B, Petersen V, Budach V, Wilhelm H, Wanke I, Hirche H, Wilke HJ, Stuschke M. Pöttgen C, et al. Among authors: stamatis g. J Clin Oncol. 2007 Nov 1;25(31):4987-92. doi: 10.1200/JCO.2007.12.5468. J Clin Oncol. 2007. PMID: 17971598 Clinical Trial.
Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
Pöttgen C, Eberhardt WE, Gauler T, Krbek T, Berkovic K, Jawad JA, Korfee S, Teschler H, Stamatis G, Stuschke M. Pöttgen C, et al. Among authors: stamatis g. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):809-15. doi: 10.1016/j.ijrobp.2009.02.022. Epub 2009 May 7. Int J Radiat Oncol Biol Phys. 2010. PMID: 19427744 Clinical Trial.
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors.
Pöttgen C, Stuschke M, Graupner B, Theegarten D, Gauler T, Jendrossek V, Freitag L, Jawad JA, Gkika E, Wohlschlaeger J, Welter S, Hoiczyk M, Schuler M, Stamatis G, Eberhardt W. Pöttgen C, et al. Among authors: stamatis g. BMC Cancer. 2015 May 6;15:363. doi: 10.1186/s12885-015-1389-4. BMC Cancer. 2015. PMID: 25943191 Free PMC article.
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W, Kimmich M, Fischer B, Schmidberger H, De Ruysscher D, Belka C, Cordes S, Hepp R, Lütke-Brintrup D, Lehmann N, Schuler M, Jöckel KH, Stamatis G, Stuschke M. Eberhardt WE, et al. Among authors: stamatis g. J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 2. J Clin Oncol. 2015. PMID: 26527789 Clinical Trial.
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Guberina M, Eberhardt W, Stuschke M, Gauler T, Aigner C, Schuler M, Stamatis G, Theegarten D, Jentzen W, Herrmann K, Pöttgen C. Guberina M, et al. Among authors: stamatis g. Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1439-1447. doi: 10.1007/s00259-019-4270-x. Epub 2019 Feb 1. Eur J Nucl Med Mol Imaging. 2019. PMID: 30710323 Clinical Trial.
159 results